Perjeta

Strong sales in breast cancer lift Roche revenues

New products Perjeta and Kadcyla lead growth. Rocketing sales of Roche's new breast cancer drugs Perjeta and Kadcyla suggest they will cushion any impact from biosimilar competition to Herceptin, which ... Last month, Roche reported new clinical data

Janssen, AZ and Roche at ESMO

In addition to using ESMO to post data that suggests Perjeta (pertuzumab) should be the new standard in breast cancer, the company also presented positive results for its investigational MEK inhibitor

Roche's Perjeta should be 'new standard' in breast cancer

Adding Roche's Perjeta to therapy with Herceptin and docetaxel has a dramatic impact on survival in patients with HER2-positive metastatic breast cancer, according to new trial data. ... With the latest CLEOPATRA data in hand the argument for the

Dive in: gaining leadership in a therapeutic area

neu (4B5) Rabbit Monoclonal Primary Antibody assay marketed by its subsidiary Ventana - used to detect breast cancer patients eligible for Herceptin, Perjeta and Kadcyla.

Back to the future

In 2013, Roche's biologics sales totalled $29.2bn. These were led by established oncology brands such as Avastin and MabThera/Rituxan, along with emerging breast cancer therapies such as Perjeta

[ Previous 5 results ] 5 6 7 8 9 10 11 12 [ Next 5 results ]